3H-spiro[2-benzofuran-1,3'-piperidine] | 54775-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异香豆素
• 英文名称: 3H-spiro[2-benzofuran-1,3'-piperidine]
• 英文别名: spiro[1H-2-benzofuran-3,3'-piperidine]
• CAS: 54775-03-0
• 化学式: C₁₂H₁₅NO
• mdl: MFCD18071869
• 分子量: 189.25
• InChiKey: KCAMDBNDUHBEBH-UHFFFAOYSA-N

物化性质

• 沸点：
  324.3±32.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS<br/>[FR] COMPOSÉS FURANOPYRIMIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE1
  申请人：DART NEUROSCIENCE LLC

  公开号：WO2019104285A1

  公开（公告）日：2019-05-31

  Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

  化学实体的呋喃嘧啶替代物的化学结构如下（I）：其中Ra具有以下所述的任何值，并含有此类化学实体的组合物；制备它们的方法；以及它们在广泛应用中的使用，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由PDE1活性或多巴胺信号传导介导的疾病；治疗神经系统疾病，中枢神经系统疾病，痴呆症，神经退行性疾病和依赖创伤的功能丧失；治疗中风，包括中风康复期间的认知和运动缺陷；促进神经保护和神经恢复；增强认知和运动训练的效率，包括动物技能训练方案；以及治疗周围疾病，包括心血管，肾脏，血液，胃肠，肝脏，癌症，生育和代谢性疾病。
• SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS
  申请人：Dart NeuroScience, LLC

  公开号：US20190177327A1

  公开（公告）日：2019-06-13

  A chemical entity of Formula (I) or Formula (II): wherein R a , R b , R e , and R f have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

  化学实体的化学式（I）或化学式（II）：其中Ra、Rb、Re和Rf可以具有本文中描述的任何值，以及包含这种化学实体的组合物；制备它们的方法；以及它们在各种方法中的使用，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由PDE1活性或多巴胺信号传导介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆、神经退行性疾病以及依赖创伤的功能丧失；治疗中风，包括中风康复期间的认知和运动功能障碍；促进神经保护和神经恢复；增强认知和运动训练的效率，包括动物技能训练方案；以及治疗外周疾病，包括心血管、肾脏、血液、胃肠、肝脏、癌症、生育和代谢紊乱。
• [EN] SPIROCYCLIC O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS<br/>[FR] INHIBITEURS SPIROCYCLIQUES D'O-GLYCOPROTÉINE-2-ACÉTAMIDO-2-DÉSOXY-3-D-GLUCOPYRANOSIDASE
  申请人：BIOGEN MA INC

  公开号：WO2021086966A1

  公开（公告）日：2021-05-06

  Described herein are compounds represented by formula (I) or formula (la) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R2, R3, R4, R5, R6, Y1, Y2, D, E, G1, G2, n and p are as defined herein.

  本文描述了由公式（I）或公式（la）表示的化合物，或其药学上可接受的盐，包括含有这些化合物的药物组合物以及制备和使用这些化合物的方法。变量R1、R2、R3、R4、R5、R6、Y1、Y2、D、E、G1、G2、n和p的定义如本文所述。
• Substituierte 1,3-Dihydrospiro (benzo(c)thiophene), Verfahren zu deren Herstellung und diese Verbindungen zur Verwendung als Arzneimittel
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0002283B1

  公开（公告）日：1983-08-24
• PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT
  申请人：H. LUNDBECK A/S

  公开号：EP0593511A1

  公开（公告）日：1994-04-27